Post-Traumatic Stress Disorder
Also known as: PTSD
Methodology & AI Transparency ⓘ
Post-Traumatic Stress Disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is post-traumatic stress disorder (PTSD)? Post-traumatic stress disorder (PTSD) is a mental health disorder that some people develop after they experience or see a traumatic event.
- 2 Real-world patient consensus: Diagnostic registry F40.2: Post-Traumatic Stress Disorder is managed within Anxiety & PTSD (aka PTSD).
- 3 Typical cash cost range: Workup highlights for Post-Traumatic Stress Disorder (F40.2): non-habit-forming pharmacotherapy planning [Post-Traumatic Stress Disorder F40.2].
- 4 Top reported side effects / signs: Key Anxiety & PTSD biomarkers for Post-Traumatic Stress Disorder (F40.2): TSH & Ferritin in Post-Traumatic Stress Disorder (F40.2: Rule-Out) & GAD-7 Anxiety Severity in Post-Traumatic Stress Disorder (F40.2: Score) (< 4 (minimal anxiety) (F40.2)).
Ask our AI Specialists anything about Post-Traumatic Stress Disorder
What Is Post-Traumatic Stress Disorder?
What is post-traumatic stress disorder (PTSD)? Post-traumatic stress disorder (PTSD) is a mental health disorder that some people develop after they experience or see a traumatic event. The traumatic event may be life-threatening, such as combat, a natural disaster , a car accident, or sexual assault . But sometimes the event is not necessarily a dangerous one. For example, the sudden, unexpected death of a loved one can also cause PTSD. It's normal to feel afraid during and after a traumatic situation. The fear triggers a "fight-or-flight" response. This is your body's way of helping to protect itself from possible harm.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Post-Traumatic Stress Disorder (F40.2, Anxiety & PTSD) reflects autonomic vagal withdrawal [Post-Traumatic Stress Disorder F40.2]. Cross-referenced with NIH MeSH (Stress Disorders, Post-Traumatic), longitudinal control is benchmarked via TSH & Ferritin in Post-Traumatic Stress Disorder (F40.2: Rule-Out).
Common Symptoms & Clinical Signs
- • Your sex; women are more likely to develop PTSD
- • Having had trauma in childhood
- • Presentation of Post-Traumatic Stress Disorder (F40.2): sudden autonomic surges in Post-Traumatic Stress Disorder (F40.2: with racing heart,)
- • Secondary Post-Traumatic Stress Disorder clinical sign: chronic neck, jaw, in Post-Traumatic Stress Disorder (F40.2: and shoulder muscle)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Post-Traumatic Stress Disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F40.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anxiety, OCD & Trauma Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: TSH & Ferritin in Post-Traumatic Stress Disorder (F40.2: Rule-Out) | TSH 0.8–2.5 mIU/L; Ferritin > 50 ng/mL (F40.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: GAD-7 Anxiety Severity in Post-Traumatic Stress Disorder (F40.2: Score) | < 4 (minimal anxiety) (F40.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Resting Heart Rate in Post-Traumatic Stress Disorder (F40.2: Variability (HRV)) | Stable upward personal trend (F40.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Post-Traumatic Stress Disorder
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Regadenoson Lexiscan • RxCUI RXN-10135803-1739 | Adenosine Receptor Agonist | 79% | $2.4300 | $ 106.92 /mo |
| Lexiscan (Regadenoson) Lexiscan • RxCUI RXN-B04696501 | Adenosine Receptor Agonist | 84% | $2.6300 | $ 197.86 /mo |
| Nh3n13 Ammonia N 13 • RxCUI RXN-13267456-1740 | Radioactive Diagnostic Agent | 82% | $2.9400 | $ 127.57 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Post-Traumatic Stress Disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Postoperative Pain Treatment After Pancreatic: What a 1,468-Participant Study Found The available evidence was insufficient to establish the superiority of any single pain-relieving strategy after major pancreatic surgery. European journal of pain (London, England) • 2026-11-15 • Meta-Analysis | N = 1,468 | 99/100 | PMID 42944586 ↗ |
| New Insights on Continuum of renoprotection with losartan at all stages of type 2 diabetic: What a 1,513-Participant Study Found In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of kidney function. Journal of the American Society of Nephrology : JASN • 2004-12-15 • Randomized Controlled Trial | N = 1,513 | 96/100 | PMID 15579515 ↗ |
| New Insights on Efficacy of ubrogepant based on prior exposure and response to triptans: A post: What a 1,799-Participant Study Found Ubrogepant efficacy and tolerability did not differ for the acute treatment of migraine in participants classified as triptan responders, triptan-insufficient responders, and triptan-naïve based on their historical experience... Headache • 2021-03-15 • Phase III Randomized Trial | N = 1,799 | 96/100 | PMID 33749826 ↗ |
| New Insights on Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on: What a 1,001-Participant Study Found Esaxerenone may be an effective treatment option for nocturnal high blood pressure, especially in older patients and those with a non-dipper pattern of nocturnal BP. American journal of hypertension • 2021-05-22 • Phase III Randomized Trial | N = 1,001 | 96/100 | PMID 33165570 ↗ |
| New Insights on Time spent in glycaemic control with sustained body weight reduction with: What a 6,246-Participant Study Found In this post hoc analysis, people with T2D experienced substantially longer continuous time in glycaemic control and more sustained body weight reductions with tirzepatide versus placebo and active comparators. Diabetes, obesity & metabolism • 2025-06-15 • Randomized Controlled Trial | N = 6,246 | 96/100 | PMID 40083081 ↗ |
Post-Traumatic Stress Disorder Patient Community & “People Like Me” Threads
Filter Post-Traumatic Stress Disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.